For biopharma pros seeking insightful discussions and a deeper understanding of the pharma world, join Dr. Na-Ri Oh and Ian Wendt as they talk with industry leaders and luminaries to delve into biotechnology, pharmaceuticals, and healthcare.RealPharma podcast aims to challenge your viewpoints, deepen your understanding of the pharma world beyond the headlines, and explore emerging trends in medical innovation.

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/9/4/22/ba1e08cf-0dde-44e4-a26e-1c70c9bb796f_rp020_-_medical_affairs_-_final.mp3

Danny McBryan, an executive leader in the pharmaceutical industry, discusses the evolving role of medical affairs in healthcare.He highlights the importance of medical affairs in conveying the science of pharmaceutical companies and translating complex data into a meaningful narrative for healthcare providers, payers, patients, and policymakers.McBryan emphasizes the need for medical affairs to be seen as a strategic partner rather than a support function and advocates for closer collaboration between medical affairs, health economics, and outcomes research (HEOR) to demonstrate the value of drugs and address unmet needs.He also discusses the impact of digital transformation on medical affairs, including wearables, therapeutic digital solutions, social media, data analysis, and real-world evidence. McBryan envisions a future where medical affairs plays a more strategic role, engages with patients, and contributes to drug discovery and development. RESOURCES<ul><li><a href="https://www.linkedin.com/in/daniel-danny-mcbryan-8257187/" rel="nofollow">Danny MCBryan on LinkedIn</a></li><li><a href="https://medicalaffairs.org/future-medical-affairs-2030/" rel="nofollow">The Future of Medical Affairs 2030</a></li><li><a href="https://medicalaffairs.org/" rel="nofollow">Medical Affairs Professional Society</a></li></ul>

Medical Affairs Reimagined: Danny McBryan on Shaping Pharma’s Future

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/8/24/14/8b2ed8c1-6528-4c91-ad3f-49752dd466f1_rp019_-_final.mp3

In this episode, Na-Ri and Ian interview Stacey Tinianov, an independent patient advocate and founder of Advocates for Collaborative Education.They discuss the importance of patient advocacy, the role of digital health, and the future of patient engagement.Stacey shares her personal journey into patient advocacy and highlights the gaps in knowledge and understanding she experienced as a breast cancer survivor. She emphasizes the need for human-centered design in healthcare, where patients are at the center of the design, development, and deployment of programs and technologies.Stacey also discusses the impact of digital platforms on patient engagement and the importance of building relationships and engaging with patients beyond a transactional level. Patient advocacy is a multifaceted field that encompasses various areas, including clinical trial advocacy, research advocacy, and policy advocacy. The future of patient advocacy lies in the expansion of voices and the focus on improving quality of life and survivorship. Advocates play a crucial role in shaping clinical trials, ensuring patient-reported outcomes are considered, and driving policy changes. The ultimate goal is to achieve true partnerships between advocacy and industry, as well as the decentralization of clinical trials.Patient advocates can effectively communicate by understanding their motivation and goals and tailoring their language to resonate with different stakeholders. The consequences of not getting patient advocacy right include a regression to the frustrating relationship patients had with pharmaceutical companies in the past. However, progress has been made, and patient advocacy has the potential to drive positive change in healthcare. Resources:<ul><li><a href="https://www.linkedin.com/in/staceytinianov/" rel="nofollow">Stacey Tinianov on LinkedIn</a></li><li><a href="https://www.rabblehealth.com/" rel="nofollow">Rabble Health</a></li><li><a href="https://advocatecollaborative.org/" rel="nofollow">Advocates for Collaborative Education</a></li><li><a href="https://www.askican.org/" rel="nofollow">International Cancer Advocacy Network</a></li><li><a href="https://www.patientadvocate.org/" rel="nofollow">Patient Advocate Foundation</a></li></ul>

Empowering the Patient Voice: A Deep Dive into Advocacy with Stacey Tinianov

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/8/7/2/8047b02d-82f0-404d-a4c4-aad079f7cd29_rp018_-_ai_-_bates_-_final.mp3

SummaryDr. Andrée Bates, a pioneering force in the realm of artificial intelligence within the pharmaceutical industry, shares insights on the evolving role of AI in pharma, the future of healthcare innovation, and her advocacy for women in leadership.She discusses the early days of AI in pharma, the challenges faced, and the evolution of AI terminology. Dr. Bates also explores the application of AI in commercial insights and analytics, market access, drug discovery, and clinical trials.The conversation covers a wide range of topics related to the application of AI in the biopharma industry, including the use of synthetic data, digital twins, regulatory and medical affairs, market access, precision doctor targeting, and ethical implications.Dr. Andree Bates shares insights on the impact of AI on drug discovery, clinical trials, and patient care, as well as the potential for AI to revolutionize the industry. Resources<ul><li><a href="https://www.linkedin.com/in/dr-andree-bates/" rel="nofollow">Andree Bates on LinkedIn</a></li><li><a href="https://eularis.com/" rel="nofollow">Eularis</a></li><li><a href="https://www.mckinsey.com/industries/life-sciences/our-insights/ai-in-biopharma-research-a-time-to-focus-and-scale" rel="nofollow">AI in biopharma research: A time to focus and scale</a></li><li><a href="https://www.alpha-sense.com/blog/trends/ai-in-biopharma/" rel="nofollow">AI in Biopharma: Use Cases and Considerations</a></li><li><a href="https://kpmg.com/us/en/articles/2023/artificial-intelligence-biopharma.html" rel="nofollow">Artificial intelligence and its expanding role across the biopharma landscape</a></li></ul>

AI Revolution: Transforming Biopharma with Andree Bates

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/7/25/21/432d30fc-7daf-4395-86c5-72f251288593_rp017_-_pbm_-_ciaccia.mp3

SummaryIn this episode, Dr. Na-Ri Oh and Ian Wendt discuss Pharmacy Benefit Managers (PBMs) and their impact on drug pricing and patient access to medications.They are joined by Antonio Ciaccia, CEO of 46 Brooklyn Research and president of 3 Access Advisors, which provides insights into the role of PBMs in the drug supply chain.The conversation highlights the consolidation of power among the top three PBMs, their anti-competitive behaviors, and the need for increased scrutiny and regulatory measures. The discussion also explores the distorted incentive structures that favor high-cost drugs over lower-cost alternatives, leading to higher drug costs and limited access for patients.The conversation explores the impact of pharmacy benefit managers (PBMs) on drug costs and access to medications. The report states that PBMs control about 70% of all specialty drug revenue, leading to the closure of independent retail pharmacies in rural areas. The conversation emphasizes the need for transparency and accountability in the PBM industry.It also discusses the potential solutions, including market-based approaches and policy changes, to address the inefficiencies and anti-competitive behaviors of PBMs.Resources<ul><li><a href="https://www.linkedin.com/in/antonio-ciaccia-390879b/" rel="nofollow">Antonio Ciaccia on LinkedIn</a></li><li><a href="https://x.com/A_Ciaccia" rel="nofollow">Antonio Ciaccia on Twitter/X</a></li><li><a href="https://www.3axisadvisors.com/" rel="nofollow">3 Axis Advisors</a></li><li><a href="https://www.46brooklyn.com/" rel="nofollow">46 Brooklyn Research</a></li><li><a href="https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemen" rel="nofollow">FTC Interim Report on PBMs</a></li></ul>

Unmasking PBMs: Antonio Ciaccia Exposes the Hidden Power Players in Healthcare

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/7/16/23/d987ee81-c4fb-4c17-8786-7b5a4bc84334_rp016_-_340b_-_sarraille.mp3

In this episode, Dr. Na-Ri Oh and Ian Wendt discuss the 340B drug pricing program with guest William Sarraille, a healthcare law expert.They explore the origins of the program and its intended purpose. However, the program has grown exponentially and is now the second largest drug program in the country. Bill raises concerns about the lack of transparency and accountability in the program, as well as the impact on patients. He argues that the program should focus on delivering value to patients and ensuring that they benefit from the discounts.The conversation delves into the complexities and challenges of the 340B program, highlighting issues such as the patient definition, transparency, contract pharmacies, and the allocation of funds. The discussion considers the need for a more comprehensive and transparent system that ensures the benefits of the program flow to the patients. They also explore the possibility of implementing a claims data process that provides faster payment and greater certainty for both manufacturers and 340B entities.The conversation concludes with a reflection on the importance of leadership and collaboration in finding solutions to the program&#39;s problems. Resources:<ul><li><a href="https://www.linkedin.com/in/william-sarraille-634a8827/" rel="nofollow">William Sarraille on LinkedIn</a></li><li><a href="https://www.hrsa.gov/opa" rel="nofollow">HRSA 340B Information</a></li><li><a href="https://www.aha.org/fact-sheets/fact-sheet-340b-drug-pricing-program" rel="nofollow">American Hospital Information (AHA) Fact Sheet</a></li><li><a href="https://www.340bhealth.org/members/340b-program/overview/" rel="nofollow">340BHealth.org</a></li></ul>

340B Controversy: Who Really Benefits from Drug Discounts?

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/6/23/15/d8ff04a2-9179-4a89-bb38-7be6cc95f521_rp_ron_shigeta_-_final.mp3

SummaryDr. Ron Shigeta, a pioneer in the biotech startup ecosystem, shares his insights and experiences in this episode. He discusses the success of IndieBio, a biotech accelerator that demonstrated the potential of modest investments in fueling biotech innovations.Dr. Shigeta also highlights the importance of timing, luck, and having a clear vision in the biotech industry. He explains the differences between synthetic biology and pharma startups and the challenges and opportunities they present.Additionally, he discusses the factors he considers when evaluating startup opportunities and the mindset of successful entrepreneurs. Finally, he shares his perspective on managing risk in biotech startups and the personal transition of becoming a startup CEO. In this conversation, Ron Shigeta discusses the landscape of venture capital funds and startup incubators, highlighting the importance of fund size and check-writing capabilities. He also explains his attraction to the food industry and the deep structural biology of food. The convergence of food and biotech is explored, with a focus on consumer applications and health-related applications. Ron shares different strategies for innovation and offers advice for aspiring entrepreneurs. He discusses promising areas for transformational impact, including the golden age of biology and the future of food and sustainability. Chapters00:00 Introduction to Dr. Ron Shigeta01:31 Dr. Shigeta&#39;s transition from scientist to biotech startup figure05:19 The impact of IndieBio&#39;s small investment model08:43 The economics of biotech startups09:57 Different pathways in biotech: synthetic biology vs. pharma13:42 Factors in evaluating startup opportunities14:09 The mindset of successful entrepreneurs19:35 The importance of company vision and team dynamics22:23 Managing risk in biotech startups27:28 The personal transition of becoming a startup CEO31:23 The risk tolerance of entrepreneurs32:36 Venture Capital Funds and Startup Incubators37:15 The Attraction of the Food Industry42:30 Convergence of Food and Biotech46:12 Innovation in Biotech and Pharma49:37 Different Strategies for Innovation51:42 Advice for Aspiring Entrepreneurs53:47 Promising Areas for Transformational Impact01:01:26 The Golden Age of Biology01:04:51 The Impact of Whole Foods Conference01:08:49 The Future of Food and Sustainability Resources:<ul><li><a href="https://www.linkedin.com/in/startupminute/" rel="nofollow">Ron Shigeta on LinkedIn</a></li><li><a href="https://twitter.com/rshigeta" rel="nofollow">Ron Shigeta on X (Twitter)</a></li><li><a href="https://www.iaccelerate.tech/" rel="nofollow">iAccelerate</a></li></ul>

From Biotech Breakthroughs to Food Tech Revolution: Dr. Ron Shigeta's Journey

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/6/5/2/5c3b5ddc-cc08-4656-b60d-2b31925532ea_rp_ethnobotony_-_final.mp3

In this enlightening episode of the RealPharma Podcast, hosts Ian Wendt and Dr. Nari Oh sit down with Dr. Steven King, a luminary in the field of ethnobotanical research and sustainable pharmaceutical development. Dr. King, currently serving as the Chief Sustainable Supply, Ethnobotanical Research, and IP Officer at Jaguar Health, shares his remarkable journey from a young adventurer in the Amazon rainforest to a pioneering figure in the integration of traditional botanical knowledge with modern medicine.Join us as we delve into the fascinating world of ethnobotany, exploring how Dr. King&#39;s lifelong passion for plant-based healing has led to groundbreaking developments in the pharmaceutical industry. Discover the story behind the Croton lechleri tree, popularly known as the Dragon&#39;s Blood tree, and how its unique properties have been harnessed to create an FDA-approved medication derived from this Amazonian marvel.Dr. King offers insights into his early experiences living with indigenous communities in South America, learning about their traditional uses of plants for medicine, and the ethical considerations involved in bringing these ancient practices into the global market. We discuss the importance of sustainability and respectful collaboration with local communities, emphasizing the crucial balance between conservation and commerce.This episode also touches on the broader implications of Dr. King’s work, from his contributions to the Healing Forest Conservatory to the role of bioethics in the commercialization of traditional knowledge. As the conversation unfolds, we explore the exciting future of plant-based therapeutics and the potential for ethnobotanical research to address some of the most pressing health challenges of our time.Tune in for a captivating discussion that spans decades of exploration, scientific discovery, and cultural exchange, highlighting how ancient wisdom can inform and transform modern healthcare. Chapters00:00 Introduction to Ethnobotany02:04 Biocultural Diversity and Pharmaceutical Development13:20 The Croton lechleri Tree and its Medicinal Uses15:59 Ethnobotanical Research vs. Traditional Drug Development21:39 Intellectual Property and Benefit-Sharing24:27 Ethical and Sustainable Practices in Working with Indigenous Communities28:27 Respecting Indigenous Knowledge and Rights in Plant-Based Medicine Development34:03 The Financial Benefits of Commercializing Plant-Based Drugs for Indigenous Communities36:23 The Potential Therapeutic Applications of Psychedelic Research Resources:<ul><li><a href="https://www.linkedin.com/in/steven-king-679b506/" rel="nofollow">Dr. Steven King - LinkedIn</a></li><li><a href="https://a.co/d/fmnw9ht" rel="nofollow">One River: Explorations and Discoveries in the Amazon Rain Forest</a></li><li><a href="https://a.co/d/hebN8jK" rel="nofollow">Plants, People, and Culture: The Science of Ethnobotany</a></li></ul>

From the Forest to your Pharmacy: Dr. Steven King's Ethnobotanical Journey

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/3/20/12/848c88d6-7dbe-4c43-9a79-78b56f3a180a_rp010-final.mp3

<h2>Command the Room: Dr. Laura Sicola&#39;s Strategies for Executive Communication Excellence</h2> <h3>Hosts: Dr. Na-Ri Oh and Ian Wendt</h3><h3> </h3>In this episode of the Real Pharma Podcast, we delve into the intricacies of effective executive communication with Dr. Laura Sicola, a renowned expert in leadership communication and cognitive linguistics. Dr. Sicola has spent over two decades transforming top-level executives into confident, inspiring leaders. Her unique approach, grounded in cognitive linguistics, empowers professionals to communicate their passion and expertise effectively, ensuring they get the buy-in they need for the results they want.Join us as we explore these topics and more, providing valuable insights for pharma professionals and anyone looking to enhance their executive communication skills. Dr. Sicola&#39;s expertise offers a roadmap to becoming a more effective and inspiring leader. Chapters00:00:00 - Introduction to WIFM: What&#39;s In It For Me?00:00:34 - Real Pharma Podcast Introduction00:01:02 - Introducing Dr. Laura Sicola00:02:37 - Welcome and TEDx Talk Discussion00:03:51 - Defining Linguistics00:04:41 - Importance of How You Say It00:05:52 - The Myth of Content vs. Delivery00:07:01 - The Linguistic Glass Ceiling00:09:06 - Transitioning from Technical Expertise to Leadership00:11:04 - Your Work Speaks for Itself, But Not for You00:12:24 - Developing Leadership Skills00:13:07 - The Challenge of Self-Awareness00:15:33 - Recording Yourself for Self-Diagnosis00:17:16 - Impact of COVID on Communication00:18:48 - Basic Skills for Effective Communication00:20:14 - Executive Presentations: What&#39;s In It For Them?00:23:05 - Seeking Constructive Feedback00:25:27 - Common Reasons for Seeking Coaching00:27:05 - The Expert&#39;s Curse00:29:37 - The Gift of Clear Feedback00:30:39 - Proactively Seeking Feedback00:32:14 - Questions to Ask for Constructive Feedback00:35:01 - The Importance of Diverse Feedback00:36:20 - Communicating Complex Data Effectively00:37:04 - The Role of Slide Design in Communication00:40:13 - The Value of Interpretation and Insights00:41:17 - Two Versions of PowerPoint: Pre-Read and Presentation00:43:08 - The $200 is $200 RuleResourcesFind Dr. Laura Sicola on:<ul><li><a href="https://www.linkedin.com/in/drlaurasicola/" rel="nofollow">LinkedIn</a></li><li><a href="https://x.com/laurasicola?lang=en" rel="nofollow">Twitter</a></li><li><a href="http://laurasicola.com" rel="nofollow">laurasicola.com</a></li><li><a href="https://www.amazon.com/Speaking-Influence-Mastering-Leadership-Voice/dp/B07QJ29BB8/?_encoding=UTF8&content-id=amzn1.sym.cf86ec3a-68a6-43e9-8115-04171136930a&pd_rd_r=cbb6d21e-92b4-40e9-bddf-50adbd1fc728&pd_rd_w=ACxnC&pd_rd_wg=8edpT&pf_rd_p=cf86ec3a-68a6-43e9-8115-04171136930a&pf_rd_r=142-0442816-0346809&ref_=aufs_ap_sc_dsk" rel="nofollow">Speaking To Influence</a></li><li><a href="https://youtu.be/02EJ1IdC6tE?si=Z0-ZoSCLZ5K7-eZL" rel="nofollow">TEDx Talk</a></li></ul>

Command the Room: Dr. Laura Sicola's Strategies for Executive Communication Excellence

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/5/20/1/0213a1a5-6f1d-4304-b26c-78ec2d2897c1_rp_drug_importation_-_final.mp3

SummaryIlisa Bernstein, a senior Vice President at the American Pharmacists Association, discusses the history and current landscape of drug importation policies with a focus on Florida&#39;s program.Safety concerns, supply chain issues, and intellectual property rights are key considerations. The impact on the Canadian drug supply and the transparency of imported drugs for consumers are also discussed. Manufacturer concerns regarding rebates and discounts, as well as potential oversupply and export restrictions, are highlighted. The conversation explores the complexities and concerns surrounding drug importation programs. It discusses the mechanisms that manufacturers may use to control drug importation, such as restricting volume or increasing prices. The potential impact on the drug supply in Canada and the need for policies to protect it are also examined. The logistical challenges at the border and the vulnerabilities in the drug supply chain are highlighted. The importance of maintaining patient confidence in drug quality and the risks associated with personal drug importation are discussed. The conversation concludes by considering alternative solutions to lower drug prices and the inspiration drawn from historical figures. Chapters00:00 Introduction of Ilisa Bernstein01:19 Background on Drug Importation08:21 Safety Concerns10:04 Supply Chain and Drug Source14:58 Transparency and IP Issues20:57 Consumer Transparency and NDC Numbers21:10 Intellectual Property Concerns22:59 Challenges and Points of Contention25:12 Manufacturer Concerns: Rebates and Discounts28:06 Oversupply and Export Restrictions29:09 Mechanisms to Control Drug Importation30:39 Policies to Protect Drug Supply in Canada31:12 Logistical Challenges at the Border33:07 Vulnerabilities in the Drug Supply Chain35:03 Maintaining Patient Confidence in Drug Quality36:31 Risks Before the Border38:01 Complexities and Concerns for Community Pharmacists41:31 The Future of Drug Importation Programs44:00 The Motivation Behind Drug Importation Programs46:01 Exploring Other Solutions to Lower Drug Prices48:19 The Illegality of Personal Drug Importation49:05 Balancing Cost Savings and Patient Safety50:02 Inspiration from Historical Figures Resources:<ul><li><a href="https://www.linkedin.com/in/ilisa-bernstein-b67222174/" rel="nofollow">Ilisa Bernstein</a></li></ul> <ul><li><a href="https://www.pharmacist.com/" rel="nofollow">American Pharmacists Association</a></li></ul> <ul><li><a href="https://www.safemedicines.org/" rel="nofollow">The Partnership for Safe Medicines</a></li></ul>

Drug Importation Debate: Ilisa Bernstein on the Global Pill

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/5/2/20/71d2100d-045e-491b-b648-02445dbff140_rp_recruiting_2_-final.mp3

SummaryIn this episode, Kristiaan Rawlings discusses the 2024-2025 Commercial Market Update and Salary Guide produced by EPM Scientific. The life sciences sector remains resilient due to aging populations, scientific advances, and robust investment. Hiring practices and compensation are influenced by these factors across the Americas, Europe, and APAC regions. The hiring focus has shifted from life-threatening diseases to more common health issues, such as dermatology and respiratory diseases. The most in-demand roles include marketing, commercial operations (salesforce effectiveness, commercial analytics, and training), and sales. Market access roles have seen less demand. Despite the availability of talent, salaries have remained high or even increased. In this conversation, Kristiaan Rawlings discusses the current trends in the life sciences job market, specifically in the commercial operations field. He explains the increase in demand for talent, the impact of title deflation, and the rise in salaries. He also highlights the regional differences in job opportunities, with a shift towards the East Coast of the United States. Additionally, he touches on the importance of executive presence and the return of in-person networking events. Overall, the conversation provides valuable insights into the evolving landscape of the life sciences job market. Chapters00:00 High Demand for Marketing Roles04:26 Focus on Core Areas with Existing Blockbuster Products05:53 Sought-After Skills for Commercial Operations and Product Launches13:54 Challenges with LinkedIn Applications and Fake Job Postings24:25 Selective Market Based on Therapy Area and Experience24:51 The Three Pillars of Focus: Salesforce Effectiveness, Commercial Analytics, and Training25:21 High Demand for Talent in Incentive Compensation, Analytics, and Competitive Intelligence26:17 Sales Roles in High Demand During Product Launches26:46 Quiet Market in the Field of Market Access27:14 Salaries Holding Strong or Increasing Despite High Supply of Talent32:30 Geography Becoming Less of a Factor in Salary and Opportunity41:08 High Demand for Medical Affairs and Health Economics44:01 The Importance of Executive Presence and Networking for Career Success Resources<ul><li><a href="https://www.linkedin.com/in/kristiaan-rawlings-826772b5/" rel="nofollow">Kristiaan Rawlings - LinkedIn</a></li></ul> <ul><li><a href="https://www.dropbox.com/scl/fi/uqitk3wgudpp56cv1niyg/Commercial-Market-Update-and-Salary-Guide.pdf?dl=0&rlkey=eqqpy2hfw5cjcmqcv64zkvf5g&st=l1qv1kik" rel="nofollow">2024/2025 EPM Commercial Update and Salary Guide</a></li></ul>

Navigating Your Biopharma Career: A Masterclass with Recruiter Kristiaan Rawlings

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/3/29/2/34cdd5ea-a6dc-4bf6-ade2-fbe3dd44a33e_rp013-final.mp3

SummaryIn this episode, hosts Ian Wendt and Dr. Na-Ri Oh , and guest Kira Dineen discuss the intersection of genomics and healthcare. They explore the concept of personalized medicine and how advancements in genomics are revolutionizing healthcare. Kira shares her personal journey and the inspiration behind her DNA Today podcast. The conversation delves into the technology behind personalized medicine and the challenges of building comprehensive genetic databases. The ethical considerations of genomics, including access to information and the potential misuse of genetic data, are also explored. The episode concludes with a discussion on the need for ethical frameworks to keep pace with technological advancements in genomics. The conversation explores the controversial topic of gene editing, particularly the use of CRISPR technology. The hosts discuss the ethical considerations and the choice of genetic targets for editing. They also touch on the accessibility and long-term consequences of CRISPR. The conversation then shifts to the cost of treatment and the role of genetic testing in drug development. The potential of AI in genetic research is explored, as well as the future of personalized medicine. The episode concludes with a discussion on professional motivation and the importance of networking. Chapters00:00 Introduction to Kira Dineen and the Intersection of Genomics and Healthcare02:07 Genomics and Personalized Medicine04:13 Kira Dineen&#39;s Personal Journey and the DNA Today Podcast08:08 The Trend Towards Personalized Medicine in Biopharma10:11 The Technology Behind Personalized Medicine12:39 Building Databases and Overcoming Barriers15:18 Ethical Considerations in Genomics20:39 Ethics and the Use of Genetic Information24:06 Ethics Keeping Pace with Technological Advances25:44 Managing Ethical Considerations in Genetic Research27:21 Controversial Gene Editing28:18 Choosing Genetic Targets29:10 Ethical Considerations29:44 Accessibility of CRISPR30:13 Long-Term Consequences of CRISPR32:51 Healthcare Equity and Cost of Treatment34:25 Cost of Genomic Sequencing35:22 Genetic Testing and Drug Development38:13 Role of Genetic Testing in Clinical Trials42:20 AI in Genetic Research46:34 Future of Personalized Medicine49:56 Professional Motivation and Networking Resources:<ul><li>Kira Dineen, MS, LCGC, CG(ASCP)CM (<a href="https://www.linkedin.com/in/kiradineen/" rel="nofollow">LInkedIn</a>, <a href="https://twitter.com/KiraDineen" rel="nofollow">Twitter</a>)</li><li><a href="http://dnatoday.com/" rel="nofollow">DNAtoday.com</a></li><li><a href="https://www.amazon.com/Breath-Salt-Patients-Families-Medicine/dp/1948836378" rel="nofollow">Breath from Salt</a> (DNA Today author interview <a href="https://dnapodcast.com/episodes/2021/5/7/147-cf-series-bijal-trivedi-on-breath-from-salt" rel="nofollow">Episode #147</a>)</li><li><a href="https://dnapodcast.com/episodes/2023/6/241-nbcs-maury-povich-on-paternity-testing16" rel="nofollow">Maury Povich interview on DNA Today</a> </li><li><a href="https://podcasts.apple.com/us/podcast/patient-empowerment-program-a-rare-disease-podcast/id1624577541" rel="nofollow">Patient Empowerment Program: A Rare Disease Podcast</a> </li></ul>

Pioneering Precision: Kira Dineen on Genetics' Role in Tailored Therapies

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/3/9/13/24251bc3-3e90-4479-8bef-9a31276135b7_rp009-final.mp3

Dive into the high-stakes world of Venture Capital in biopharma with Jim Trenkle! Have you ever wondered what it takes to turn groundbreaking scientific discoveries into life-saving treatments? What role do venture capitalists play in this thrilling journey from the lab to the clinic? This episode peels back the curtain on the biopharma venture capital scene, revealing the risks, rewards, and radical innovations driving the future of healthcare. Join hosts Dr. Na-Ri Oh and Ian Wendt as they explore with Jim the secrets of successful biopharma investments, the challenges of navigating the complex landscape of medical research funding, and the thrilling potential of the next big breakthroughs. Don&#39;t miss this conversation that could change the way you see medicine and innovation.In this episode, Jim Trenkle, a partner at Nova Holdings, shares insights on venture capital in the biopharma industry. He explains the different stages of investment, from seed rounds to IPOs, and the role of venture capitalists in providing capital and expertise.Jim discusses the current state of raising capital for biotech startups, including the impact of interest rates and market conditions. He also highlights the challenges and evaluation criteria in biotech VC, emphasizing the importance of a well-thought-out plan and addressing unmet needs.Jim Trenkle also discusses his own career path and the importance of finding work that has a deeper impact. He shares his journey from being a medicinal chemist to venture capital, highlighting the value of lifelong learning and broadening one&#39;s impact. Trenkle also discusses the challenges and skills required in venture capital, emphasizing the need for humility and the ability to make decisions that have a real impact. He reflects on the lessons learned from the Theranos scandal and the role of venture capitalists in evaluating companies.Trenkle explores the reasons behind company closures and failures in the biopharma industry and the potential for innovation and technological advances to shape the future of venture capital. He concludes with advice on career growth and the importance of following one&#39;s passion. Chapters00:00 Introduction of Jim Trankel 01:01 Understanding Venture Capital in BioPharma 07:59 The Current State of Raising Capital for Biotech Startups 11:23 The Landscape of Biotech Funding 16:25 Challenges and Evaluation in Biotech VC 23:16 What Does Good Look Like and Pitfalls to Avoid 31:19 Jim Trankel&#39;s Career Path 31:59 Career Path and Impact 35:19 Challenges and Skills in Venture 37:05 Evaluating Companies and Capital Allocators 38:23 Lessons from Theranos 46:01 Company Closures and Failures 52:42 The Future of VC in Biopharma 58:32 Advice and Mentors Resources<ul><li>Jim Trenkle, PhD <a href="https://www.linkedin.com/in/jim-trenkle-phd-237bbb/" rel="nofollow">(LinkedIn)</a></li><li><a href="https://novoholdings.dk/" rel="nofollow">Novo Holdings</a></li></ul> <a href="https://pitchbook.com/news/reports/2024-us-venture-capital-outlook" rel="nofollow">1. **2024 US Venture Capital Outlook | PitchBook**: Provides predictions for the US VC ecosystem in 2024, including insights on unicorn companies and valuation trends</a> <a href="https://foundersnetwork.com/blog/2024-venture-capital-trends/" rel="nofollow">2. **2024 Venture Capital Trends: Opportunities and Challenges - Founders Network**: Discusses the shift towards startups demonstrating strong fundamentals and a clear path to profitability</a> <a href="https://www.cambridgeassociates.com/insight/2024-outlook-private-equity-venture-capital/" rel="nofollow">3. **2024 Outlook: Private Equity &amp; Venture Capital - Cambridge Associates**: Highlights the expected increase in capital flows to private European turnaround and value strategies</a> <a href="https://www.gtlaw.com/en/insights/2024/01/published-articles/5-trends-to-watch-2024-venture-capital" rel="nofollow">4. **5 Trends to Watch: 2024 Venture Capital | Greenberg Traurig LLP**: Governance issues and IPO momentum are among the trends highlighted for VC in 2024</a> <a href="https://www.bain.com/insights/global-venture-capital-outlook-latest-trends-snap-chart/" rel="nofollow">5. **Global Venture Capital Outlook: The Latest Trends | Bain &amp; Company**: Covers a broad range of industries and the impact on venture capital funding</a> <a href="https://explodingtopics.com/blog/vc-trends" rel="nofollow">6. **4 Important Venture Capital Trends (2024-2026) | Exploding Topics**: Explores equity crowdfunding platforms like WeFunder and StartEngine, highlighting their growth and impact on the startup funding landscape</a> <a href="https://www.ey.com/en_us/growth/venture-capital/venture-capital-market-to-seek-new-floor-in-2024" rel="nofollow">7. **Venture capital market to seek new floor in 2024 | EY - US**: Provides insights into the economic headwinds impacting investor appetite and the outlook for the VC market in 2024</a> <a href="https://coresignal.com/blog/venture-capital-trends/" rel="nofollow">8. **5 Venture Capital Trends to Watch in 2024 | Coresignal**: Discusses portfolio diversification and the role of cryptocurrency in VC trends</a> <a href="https://www.allvuesystems.com/resources/top-trends-in-venture-capital/" rel="nofollow">9. **Top 4 Trends in Venture Capital for 2024 | Allvue Systems**: Highlights the opportunities in the European VC market and the ongoing interest in AI and biotech startups</a> <a href="https://www2.deloitte.com/us/en/pages/audit/articles/trends-in-venture-capital.html" rel="nofollow">10. **2024 Trends in Venture Capital | Deloitte US**: Offers a perspective on the state of the IPO market, with AI as a potential catalyst for change</a>

Dive into the high-stakes world of Venture Capital in biopharma with Jim Trenkle! Have you ever wondered what it takes to turn groundbreaking scientific discoveries into life-saving treatments? What role do venture capitalists play in this thrilling journey from the lab to the clinic? This episode peels back the curtain on the biopharma venture capital scene, revealing the risks, rewards, and radical innovations driving the future of healthcare. Join hosts Dr. Na-Ri Oh and Ian Wendt as they explore with Jim the secrets of successful biopharma investments, the challenges of navigating the complex landscape of medical research funding, and the thrilling potential of the next big breakthroughs. Don't miss this conversation that could change the way you see medicine and innovation.

In this episode, Jim Trenkle, a partner at Nova Holdings, shares insights on venture capital in the biopharma industry. He explains the different stages of investment, from seed rounds to IPOs, and the role of venture capitalists in providing capital and expertise.

Jim discusses the current state of raising capital for biotech startups, including the impact of interest rates and market conditions. He also highlights the challenges and evaluation criteria in biotech VC, emphasizing the importance of a well-thought-out plan and addressing unmet needs. Additionally, Jim discusses hot areas and trends in biotech investing and shares his atypical career path.

Jim Trenkle also discusses his own career path and the importance of finding work that has a deeper impact. He shares his journey from being a medicinal chemist to venture capital, highlighting the value of lifelong learning and broadening one's impact. Trenkle also discusses the challenges and skills required in venture capital, emphasizing the need for humility and the ability to make decisions that have a real impact. He reflects on the lessons learned from the Theranos scandal and the role of venture capitalists in evaluating companies.

Trenkle explores the reasons behind company closures and failures in the biopharma industry and the potential for innovation and technological advances to shape the future of venture capital. He concludes with advice on career growth and the importance of following one's passion.


Chapters
00:00 Introduction of Jim Trankel

01:01 Understanding Venture Capital in BioPharma

07:59 The Current State of Raising Capital for Biotech startups

11:23 The Landscape of Biotech Funding

16:25 Challenges and Evaluation in Biotech VC

23:16 What Does Good Look Like and Pitfalls to Avoid

31:19 Jim Trankel's Career Path

31:59 Career Path and Impact

35:19 Challenges and Skills in Venture

37:05 Evaluating Companies and Capital Allocators

38:23 Lessons from Theranos

46:01 Company Closures and Failures

52:42 The Future of VC in Biopharma

58:32 Advice and Mentors

Venture Capital & Biopharma: Jim Trenkle on Pioneering Health Innovation

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/3/1/3/933816c9-6b5a-4fa3-a400-51ed3ad4d90b_rp008-final.mp3

Join us on a deep dive into the world of Health Economics and Outcomes Research (HEOR) with the remarkable Iris Tam, PharmD, a luminary in value-based evidence generation within the biopharma industry. In this episode, our hosts Ian and Na-Ri explore with Iris the critical role of HEOR in transforming today&#39;s pharmaceutical landscape, from drug development to global marketing strategies and beyond. Unpacking the complexities of HEOR, they delve into its definition, significance, and the evolving importance of this field in aligning drug development with payer expectations and patient outcomes. Iris shares invaluable insights on the key elements that payers scrutinize in HEOR studies, and the strategic considerations essential for successful global product launches.  Ethical considerations in HEOR research also take center stage, highlighting the responsibility of ensuring integrity and patient-centricity in evidence generation. For professionals eager to make their mark in HEOR or advance their careers, Iris offers sage advice, emphasizing the need for robust data, the value of learning from post-mortems, and the art of using failures to forge successful future strategies. This episode is not just an exploration of HEOR&#39;s impact on healthcare but a guide to understanding the challenges of demonstrating product value and the crucial role of user adoption. Whether you&#39;re a seasoned professional or new to the field, Iris&#39;s journey and insights offer inspiration and guidance for navigating the complexities of HEOR in the biopharma industry. Chapters<ul><li>00:00 Introduction of Iris Tam</li></ul> <ul><li>02:08 Definition and Significance of HEOR</li></ul> <ul><li>04:07 Evolution and Increasing Role of HEOR</li></ul> <ul><li>07:49 Components of HEOR: Health Economics and Outcomes Research</li></ul> <ul><li>10:26 Impact of HEOR on Drug Development and Marketing Strategies</li></ul> <ul><li>25:46 Key Elements for Payers in HUR Studies</li></ul> <ul><li>38:47 Considerations for HUR in Global Launches</li></ul> <ul><li>41:35 Ethical Considerations in HUR Research</li></ul> <ul><li>46:41 Skills and Experiences for Success in HUR</li></ul> <ul><li>51:49 The importance of user adoption</li></ul> <ul><li>52:01 Learning from post mortems</li></ul> <ul><li>53:01 Using failures to inform future strategies</li></ul> <ul><li>53:55 The challenge of proving product benefits</li></ul> <ul><li>54:23 Closing thoughts and advice</li></ul> Resources:<ul><li><a href="https://www.linkedin.com/in/iris-tam-8394a55/" rel="nofollow">Iris Tam</a></li></ul> <ul><li><a href="https://1coeus.com/" rel="nofollow">Coeus Consulting Group</a></li></ul> <ul><li><a href="https://www.ispor.org/heor-resources" rel="nofollow">ISPOR HEOR Resources</a></li></ul>﻿<ul><li><a href="https://www.ispor.org/heor-resources/about-heor/top-10-heor-trends" rel="nofollow">ISPOR Top 10 HEOR Trends</a></li></ul>

Join us on a deep dive into the world of Health Economics and Outcomes Research (HEOR) with the remarkable Iris Tam, PharmD, a luminary in value-based evidence generation within the biopharma industry. In this episode, our hosts Ian and Na-Ri explore with Iris the critical role of HEOR in transforming today's pharmaceutical landscape, from drug development to global marketing strategies and beyond.

Unpacking the complexities of HEOR, they delve into its definition, significance, and the evolving importance of this field in aligning drug development with payer expectations and patient outcomes. Iris shares invaluable insights on the key elements that payers scrutinize in HEOR studies, and the strategic considerations essential for successful global product launches. 

Ethical considerations in HEOR research also take center stage, highlighting the responsibility of ensuring integrity and patient-centricity in evidence generation. For professionals eager to make their mark in HEOR or advance their careers, Iris offers sage advice, emphasizing the need for robust data, the value of learning from post-mortems, and the art of using failures to forge successful future strategies.

This episode is not just an exploration of HEOR's impact on healthcare but a guide to understanding the challenges of demonstrating product value and the crucial role of user adoption. Whether you're a seasoned professional or new to the field, Iris's journey and insights offer inspiration and guidance for navigating the complexities of HEOR in the biopharma industry.

Chapters
00:00 Introduction of Iris Tam

02:08 Definition and Significance of HEOR

04:07 Evolution and Increasing Role of HEOR

07:49 Components of HEOR: Health Economics and Outcomes Research

10:26 Impact of HEOR on Drug Development and Marketing Strategies

25:46 Key Elements for Payers in HUR Studies

38:47 Considerations for HUR in Global Launches

41:35 Ethical Considerations in HUR Research

46:41 Skills and Experiences for Success in HUR

51:49 The importance of user adoption

52:01 Learning from post mortems

53:01 Using failures to inform future strategies

53:55 The challenge of proving product benefits

54:23 Closing thoughts and advice

Decoding HEOR: Iris Tam's Insights on Pharma's Value-Based Future

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/2/25/17/9f3e8b67-377a-44e6-b073-cdb04b511136_rp007_-_final.mp3

Dive into the world of fertility with Shelley Bailey, the visionary founder and CEO of Famlee Fertility, on our latest episode. Discover Shelley&#39;s personal journey that led to the creation of Famlee, a company revolutionizing the fertility landscape with its home-based testing and clinical treatments aimed at empowering women to understand and enhance their fertility. In this enlightening conversation, Shelley unravels the role of Famlee in supporting women through their fertility treatment journey, debunking common myths and misconceptions that surround fertility. Learn about the holistic approach and tailored treatment plans Famlee offers, designed to balance hormones and improve fertility from the comfort of home. Tune in to gain valuable insights into overcoming fertility challenges, the importance of personalized care, and the future of fertility treatments. Whether you&#39;re navigating your own fertility journey or simply interested in the innovations transforming women&#39;s health, this episode promises to enlighten, inspire, and empower. Chapters:00:00 Introduction to Shelley Bailey and Famlee Fertility 04:02 Shelley&#39;s Personal Journey and Inspiration for Starting Famlee 09:47 The Role of Famlee in the Fertility Treatment Journey 14:38 Positioning Famlee in the Healthcare Landscape 17:10 Common Myths and Misconceptions about Female and Male Fertility 23:39 The Journey with Famlee: Holistic Approach and Treatment Plan 32:47 Challenges Faced as a Founder in the Fertility Sector 42:15 Future Plans and Expansion for Famlee 43:49 Mentors and Inspiration in Shelley&#39;s Entrepreneurial Journey Resources: <ul><li><a href="https://famlee.com/" rel="nofollow">Famlee Fertility</a></li></ul> <ul><li><a href="https://www.linkedin.com/in/shelleyjbailey/" rel="nofollow">Shelley Bailey</a>, CEO and Founder of Famlee</li></ul> <ul><li>**Understanding Fertility: The Basics** - HHS Office of Population Affairs: Explore fundamental aspects of fertility, including menstrual cycle and fertility awareness.</li></ul><a href="https://opa.hhs.gov/adolescent-health/reproductive-health/understanding-fertility-basics" rel="nofollow">https://opa.hhs.gov/adolescent-health/reproductive-health/understanding-fertility-basics</a> <ul><li>**RESOLVE: The National Infertility Association**: Offers detailed information on the female reproductive system and resources for managing infertility stress and relationships. Support groups and professional help are also available.</li></ul><a href="https://resolve.org/what-are-my-options/understanding-infertility/" rel="nofollow">https://resolve.org/what-are-my-options/understanding-infertility/</a> <ul><li>**Female Fertility: Why Lifestyle Choices Count - Mayo Clinic**: Provides insights into how lifestyle choices impact fertility and offers practical tips for maintaining a healthy lifestyle to improve fertility.</li></ul><a href="https://www.mayoclinic.org/healthy-lifestyle/getting-pregnant/in-depth/fertility/art-20047584" rel="nofollow">https://www.mayoclinic.org/healthy-lifestyle/getting-pregnant/in-depth/fertility/art-20047584</a> <ul><li>**Fertility.com**: Contains comprehensive information about female fertility facts, age, and the reproductive system, including the menstrual cycle and the male’s role in conception.</li></ul><a href="https://us.fertility.com/female-fertility" rel="nofollow">https://us.fertility.com/female-fertility</a> <ul><li>**Your Fertility**: Offers a range of fact sheets on topics like the effects of caffeine, alcohol, and smoking on reproductive outcomes, understanding ovulation, and the role of exercise in improving fertility.</li></ul><a href="https://www.yourfertility.org.au/" rel="nofollow">https://www.yourfertility.org.au</a> <ul><li>**Infertility 101 from RESOLVE**: Provides an overview of infertility basics, along with support options, including online communities and advocacy information.</li></ul><a href="https://resolve.org/what-are-my-options/infertility-101/" rel="nofollow">https://resolve.org/what-are-my-options/infertility-101/</a>

Dive into the world of fertility with Shelley Bailey, the visionary founder and CEO of Famlee Fertility, on our latest episode. Discover Shelley's personal journey that led to the creation of Famlee, a company revolutionizing the fertility landscape with its home-based testing and clinical treatments aimed at empowering women to understand and enhance their fertility.

In this enlightening conversation, Shelley unravels the role of Famlee in supporting women through their fertility treatment journey, debunking common myths and misconceptions that surround fertility. Learn about the holistic approach and tailored treatment plans Famlee offers, designed to balance hormones and improve fertility from the comfort of home.

Tune in to gain valuable insights into overcoming fertility challenges, the importance of personalized care, and the future of fertility treatments. Whether you're navigating your own fertility journey or simply interested in the innovations transforming women's health, this episode promises to enlighten, inspire, and empower.

Chapters:
00:00 Introduction to Shelley Bailey and Famlee Fertility

04:02 Shelley's Personal Journey and Inspiration for Starting Famlee

09:47 The Role of Famlee in the Fertility Treatment Journey

14:38 Positioning Famlee in the Healthcare Landscape

17:10 Common Myths and Misconceptions about Female and Male Fertility

23:39 The Journey with Famlee: Holistic Approach and Treatment Plan

32:47 Challenges Faced as a Founder in the Fertility Sector

42:15 Future Plans and Expansion for Famlee

43:49 Mentors and Inspiration in Shelley's Entrepreneurial Journey

Redefining Fertility Care: Shelley Bailey's Journey with Famlee

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/2/25/13/74400545-d947-466f-aa8e-226e443867eb_rp006-final.mp3

Dr. Jerome Adams, the 20th US Surgeon General, discusses various topics related to public health, including Operation Warp Speed, diversity in clinical trials, improving healthcare access and outcomes, addressing health inequities, collaborative approaches in healthcare, challenges with pricing models, the importance of prevention and health literacy, and lessons learned from COVID-19.In this conversation, Dr. Jerome Adams discusses the impact of political pandering on public health messaging and the erosion of trust in the CDC. He emphasizes the need for proper funding and communication in the CDC to effectively respond to public health crises. Dr. Adams also highlights the importance of practical information and listening to the public, as well as supporting public health workers. He suggests protecting the independence of CDC directors and Surgeon Generals to instill trust in the organization.The conversation also touches on the reputation of the pharma industry and the paradox of trust and distrust in public health organizations. Dr. Adams concludes by sharing his guiding principles of caring and finding common ground. Takeaways<ul><li>Operation Warp Speed was a significant achievement in public health, demonstrating the collaboration between the public and private sectors to develop and distribute COVID-19 vaccines.</li><li>Diversity in clinical trials is crucial to ensure that medications and treatments are effective for all populations.</li><li>Improving healthcare access and outcomes requires a holistic approach that addresses social determinants of health and promotes health equity.</li><li>Collaboration between different stakeholders, including the government, private industry, and the community, is essential to drive positive change in healthcare.</li><li>Pricing models in the pharmaceutical industry need to be reevaluated to ensure the affordability and accessibility of medications for all individuals. Political pandering can have a detrimental impact on public health messaging and erode trust in public health organizations.</li><li>Proper funding and communication are essential for the CDC to respond to public health crises effectively.</li><li>Practical information and listening to the public are crucial in public health communication.</li><li>Supporting and retaining public health workers is vital for a strong public health infrastructure.</li><li>Protecting the independence of CDC directors and Surgeon Generals can help build trust in the organization.</li><li>The pharma industry needs to address issues of inequity and community engagement to improve public perception.</li><li>There is a paradox of trust and distrust in public health organizations, which requires addressing underlying issues.</li><li>Caring and finding common ground are important guiding principles in public health work.</li></ul> Chapters00:00 Introduction to Dr. Jerome Adams 02:18 Discussion on Operation Warp Speed 05:34 Importance of Diversity in Clinical Trials 09:52 Improving Healthcare Access and Outcomes 18:03 Addressing Health Inequities 23:35 Collaborative Approach in Healthcare 25:30 Challenges with Pricing Models 30:21 Importance of Prevention and Health Literacy 35:06 Lessons Learned from COVID-19 45:57 The Impact of Political Pandering 46:53 The Perception of Political Leanings 47:40 The Erosion of Trust in the CDC 49:27 The Need for Proper Funding and Communication in the CDC 51:51 The Importance of Practical Information and Listening to the Public 53:25 The Importance of Supporting Public Health Workers 54:16 Protecting the Independence of CDC Directors and Surgeon Generals 55:47 The Reputation of the Pharma Industry 58:12 The Paradox of Trust and Distrust in Public Health Organizations 01:04:07 Guiding Principles: Caring and Finding Common Ground Resources:<ul><li><a href="https://www.linkedin.com/in/jerome-adams-md-mph-117b30122/" rel="nofollow">Dr. Jerome Adams (LinkedIn)</a></li></ul> <ul><li><a href="https://twitter.com/JeromeAdamsMD" rel="nofollow">Dr. Jerome Adams (Twitter/X)</a></li></ul> <ul><li><a href="https://www.purdue.edu/provost/health/adams.html" rel="nofollow">Dr. Jerome Adams (Purdue University)</a></li></ul> <ul><li><a href="https://a.co/d/aIoHCDr" rel="nofollow">Crisis and Chaos: Lessons from the Front Lines of the War Against Covid-19</a></li></ul> Operation Warp Speed Resources:<ul><li><a href="https://www.gao.gov/products/gao-21-319" rel="nofollow">GAO Report</a></li><li><a href="https://www.gao.gov/assets/gao-21-319.pdf" rel="nofollow">GAO Congressional Report</a></li><li><a href="https://www.hhs.gov/sites/default/files/strategy-for-distributing-covid-19-vaccine.pdf" rel="nofollow">OWS Distribution Strategy</a></li></ul>

Dr. Jerome Adams, the 20th US Surgeon General, discusses various topics related to public health, including Operation Warp Speed, diversity in clinical trials, improving healthcare access and outcomes, addressing health inequities, collaborative approaches in healthcare, challenges with pricing models, the importance of prevention and health literacy, and lessons learned from COVID-19.

In this conversation, Dr. Jerome Adams discusses the impact of political pandering on public health messaging and the erosion of trust in the CDC. He emphasizes the need for proper funding and communication in the CDC to effectively respond to public health crises. Dr. Adams also highlights the importance of practical information and listening to the public, as well as supporting public health workers. He suggests protecting the independence of CDC directors and Surgeon Generals to instill trust in the organization.

The conversation also touches on the reputation of the pharma industry and the paradox of trust and distrust in public health organizations. Dr. Adams concludes by sharing his guiding principles of caring and finding common ground.

Chapters
00:00 Introduction to Dr. Jerome Adams
02:18 Discussion on Operation Warp Speed
05:34 Importance of Diversity in Clinical Trials
09:52 Improving Healthcare Access and Outcomes
18:03 Addressing Health Inequities
23:35 Collaborative Approach in Healthcare
25:30 Challenges with Pricing Models
30:21 Importance of Prevention and Health Literacy
35:06 Lessons Learned from COVID-19
45:57 The Impact of Political Pandering
46:53 The Perception of Political Leanings
47:40 The Erosion of Trust in the CDC
49:27 The Need for Proper Funding and Communication in the CDC
51:51 The Importance of Practical Information and Listening to the Public
53:25 The Importance of Supporting Public Health Workers
54:16 Protecting the Independence of CDC Directors and Surgeon Generals
55:47 The Reputation of the Pharma Industry
58:12 The Paradox of Trust and Distrust in Public Health Organizations
01:04:07 Guiding Principles: Caring and Finding Common Ground

A Surgeon General's Perspective: Dr. Adams on Health Innovation and Equity Challenges

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/2/16/0/b27582ec-c35c-4431-9b22-731f11152861_patient-advocacy-final.mp3

Trying to understand how pharma can effectively partner with patient advocates to support better patient outcomes? In this episode, Coy Stout discusses his journey in patient advocacy and the intersection of patient advocacy, policy, and social work in the pharma industry. He shares personal stories that motivated him to get involved in the field and highlights the importance of patient-centricity in biotech companies.Coy also discusses the role of technology in patient advocacy and the challenges and controversies surrounding patient advocacy in diseases like ALS and Alzheimer&#39;s. He emphasizes the need for transparency, collaboration, and patient input in decision-making processes, especially when it comes to drug pricing and access. In this episode, Coy Stout shares his insights on patient advocacy and the importance of patient-centered care. He discusses the challenges faced by patients and the need for more diverse representation in healthcare and pharma. Coy also highlights the transformative medicine happening now and the opportunity to bring real-world expertise into the industry. He envisions a future where patients and their caregivers are actively involved in guiding research and commercialization efforts.Overall, Coy emphasizes the importance of creating space for patients and their communities to contribute to innovation in healthcare. Chapters:00:00 Introduction01:32 Motivation for Patient Advocacy04:38 Early Relationships Between Advocacy Groups and Pharma07:08 Patient-Centricity in Biotech Companies09:42 Gold Standard of Patient Advocacy10:51 Intersection of Patient Advocacy and DEI Initiatives12:45 Engaging Employees in Advocacy17:34 Role of Technology in Patient Advocacy20:50 Controversies and Challenges in Patient Advocacy31:07 Patient Advocacy in ALS and Alzheimer&#39;s Disease38:00 Balancing Patient Advocacy and Drug Pricing54:53 Closing Remarks Links:Patient Advocate Foundation (PAF) offers various patient-friendly resources to empower individuals in leading their healthcare journey. <a href="https://www.patientadvocate.org/explore-our-resources/" rel="nofollow">These resources include publications, tip sheets, webinars, and interactive materials2</a>. The American Medical Association (AMA) is dedicated to advocating for patients’ access to quality healthcare. <a href="https://www.ama-assn.org/delivering-care/patient-support-advocacy" rel="nofollow">Physicians actively work to address health disparities and fight for patients’ rights through legislative efforts and legal support</a>. National Patient Advocate Foundation (NPAF):<a href="https://www.npaf.org/" rel="nofollow">The NPAF provides additional resources to support patients in their healthcare experiences</a>.

Trying to understand how pharma can effectively partner with patient advocates to support better patient outcomes? 

In this episode, Coy Stout discusses his journey in patient advocacy and the intersection of patient advocacy, policy, and social work in the pharma industry. He shares personal stories that motivated him to get involved in the field and highlights the importance of patient-centricity in biotech companies.

Coy also discusses the role of technology in patient advocacy and the challenges and controversies surrounding patient advocacy in diseases like ALS and Alzheimer's. He emphasizes the need for transparency, collaboration, and patient input in decision-making processes, especially when it comes to drug pricing and access. In this episode, Coy Stout shares his insights on patient advocacy and the importance of patient-centered care. He discusses the challenges faced by patients and the need for more diverse representation in healthcare and pharma. Coy also highlights the transformative medicine happening now and the opportunity to bring real-world expertise into the industry. He envisions a future where patients and their caregivers are actively involved in guiding research and commercialization efforts.

Overall, Coy emphasizes the importance of creating space for patients and their communities to contribute to innovation in healthcare.



Chapters:

00:00 Introduction

01:32 Motivation for Patient Advocacy

04:38 Early Relationships Between Advocacy Groups and Pharma

07:08 Patient-Centricity in Biotech Companies

09:42 Gold Standard of Patient Advocacy

10:51 Intersection of Patient Advocacy and DEI Initiatives

12:45 Engaging Employees in Advocacy

17:34 Role of Technology in Patient Advocacy

20:50 Controversies and Challenges in Patient Advocacy

31:07 Patient Advocacy in ALS and Alzheimer's Disease

38:00 Balancing Patient Advocacy and Drug Pricing

54:53 Closing Remarks

Advocacy in Action: Coy Stout's Vision for Empowered Healthcare

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/1/25/20/4f204a42-e67b-4f46-b966-9ff64f579e90_bioengineering_-_ramadi_-_final.mp3

Dr. Khalil Ramadi, an assistant professor at New York University Abu Dhabi, discusses the field of bioengineering and his work in neuromodulation and ingestible electronics. He explains that bioengineering encompasses tinkering with biology and physiology, and its focus has shifted from building hardware tools for the clinic to devices that can be implanted in the body. Dr. Ramadi&#39;s interest in neuromodulation stems from the need to improve brain technologies and find non-invasive ways to target specific areas of the body. He also explores the potential applications of neuromodulation in areas such as obesity, eating disorders, and diabetes. The challenges in bioengineering include regulatory issues, access to innovations, and the scalability of devices. In this conversation, Khalil Ramadi discusses the field of bioengineering and its potential impact on healthcare. He shares insights on the future of bioengineering education, emphasizing the need for innovation and commercialization. Khalil also predicts advancements in personalized care and the potential for new technologies to diagnose and treat diseases. He highlights the importance of finding inspiration and overcoming challenges in the field. Lastly, he introduces Project Prana Foundation, a nonprofit organization focused on developing technologies for decentralized care. <h2>Chapters</h2>00:00 Introduction to Dr. Khalil Ramadi03:47 Defining Bioengineering06:33 Dr. Ramadi&#39;s Journey into Bioengineering10:30 The Role of a Bioengineer11:56 Focus on Neuromodulation and Ingestible Electronics16:41 The Gut-Brain Connection17:26 Applications of Neuromodulation20:38 Neuralink and the Future of Bioengineering25:05 Neuromodulation and GLP-1 Agonists29:27 Challenges in Bioengineering33:33 The Future of Pharma and Bioengineering36:18 Ensuring Access to Bioengineering Innovations40:20 The FLASH Pill and Appetite Stimulation47:02 The Future of Bioengineering Education51:10 Predictions for the Next 10 Years55:00 Finding Inspiration and Overcoming Challenges58:31 Project Prana Foundation <h2>Resources</h2>Dr. Khalil Ramadi:<a href="https://www.linkedin.com/in/khalil-ramadi/" rel="nofollow">https://www.linkedin.com/in/khalil-ramadi/</a> Ramadi Lab:<a href="http://ramadilab.com/" rel="nofollow">RamadiLab.com</a> Ingestible electronics: Science Robotics paper for gastric stimulation: <a href="https://www.science.org/doi/10.1126/scirobotics.ade9676" rel="nofollow">https://www.science.org/doi/10.1126/scirobotics.ade9676</a> Project Prana: <a href="https://www.projectprana.org/isave" rel="nofollow">https://www.projectprana.org/isave</a> Nano Robots Shrink Bladder Cancer:<a href="https://www.irbbarcelona.org/en/news/scientific/nanorobots-shrink-bladder-tumours-90" rel="nofollow">https://www.irbbarcelona.org/en/news/scientific/nanorobots-shrink-bladder-tumours-90</a> Light Powered Yeast:<a href="https://www.science.org/content/article/scientists-engineer-first-light-powered-yeast" rel="nofollow">https://www.science.org/content/article/scientists-engineer-first-light-powered-yeast</a> DNA Detection Advances:<a href="https://scitechdaily.com/rapid-disease-diagnosis-bioengineering-breakthrough-boosts-dna-detection-sensitivity-by-100x/" rel="nofollow">https://scitechdaily.com/rapid-disease-diagnosis-bioengineering-breakthrough-boosts-dna-detection-sensitivity-by-100x/</a>

Dr. Khalil Ramadi, an assistant professor at New York University Abu Dhabi, discusses the field of bioengineering and his work in neuromodulation and ingestible electronics. He explains that bioengineering encompasses tinkering with biology and physiology, and its focus has shifted from building hardware tools for the clinic to devices that can be implanted in the body.

Dr. Ramadi's interest in neuromodulation stems from the need to improve brain technologies and find non-invasive ways to target specific areas of the body. He also explores the potential applications of neuromodulation in areas such as obesity, eating disorders, and diabetes. The challenges in bioengineering include regulatory issues, access to innovations, and the scalability of devices.

In this conversation, Khalil Ramadi discusses the field of bioengineering and its potential impact on healthcare. He shares insights on the future of bioengineering education, emphasizing the need for innovation and commercialization. Khalil also predicts advancements in personalized care and the potential for new technologies to diagnose and treat diseases. He highlights the importance of finding inspiration and overcoming challenges in the field.

Lastly, he introduces Project Prana Foundation, a nonprofit organization focused on developing technologies for decentralized care.

Takeaways:
Bioengineering involves tinkering with biology and physiology to develop innovative medical devices and technologies.

Neuromodulation is a field within bioengineering that focuses on targeting specific areas of the body using electrical stimulation.

Ingestible electronics, such as the FLASH pill, have the potential to stimulate appetite and promote eating in patients with conditions like chemotherapy-induced nausea or eating disorders.

The future of bioengineering and pharma may involve the convergence of the two fields, with pharma companies incorporating bioengineering technologies into their offerings.

Ensuring access to bioengineering innovations is a challenge that requires addressing logistical, financial, and regulatory barriers. Bioengineering education should focus on innovation and commercialization to bridge the gap between research and tangible products.

Advancements in personalized care and diagnostic technologies will revolutionize healthcare.

Finding inspiration and overcoming challenges are crucial for success in bioengineering.

Project Prana Foundation is a nonprofit organization working on technologies for decentralized care.

Chapters:
00:00 Introduction to Dr. Khalil Ramadi
03:47 Defining Bioengineering
06:33 Dr. Ramadi's Journey into Bioengineering
10:30 The Role of a Bioengineer
11:56 Focus on Neuromodulation and Ingestible Electronics
16:41 The Gut-Brain Connection
17:26 Applications of Neuromodulation
20:38 Neuralink and the Future of Bioengineering
25:05 Neuromodulation and GLP-1 Agonists
29:27 Challenges in Bioengineering
33:33 The Future of Pharma and Bioengineering
36:18 Ensuring Access to Bioengineering Innovations
40:20 The FLASH Pill and Appetite Stimulation
47:02 The Future of Bioengineering Education
51:10 Predictions for the Next 10 Years
55:00 Finding Inspiration and Overcoming Challenges
58:31 Project Prana Foundation

Engineering Health: Dr. Khalil Ramadi's Vision of Bioengineering and Neuromodulation

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/1/25/15/a463de2d-37fb-43db-8737-47da706f6081_rp001_-_final.mp3

This episode discusses the biopharmaceutical job market and the impact of the COVID-19 pandemic. It explores the state of the job market, including layoffs and hiring trends in the industry. The conversation also delves into the role of recruiters in the life sciences industry and provides insights into their day-to-day activities. Additionally, it offers advice for candidates on how to approach working with recruiters and highlights the importance of building long-term relationships. The episode concludes with a discussion on the impact of technology on job applications. In this conversation, Kristiaan discusses the current hot areas in the industry, including GLP-1s, dermatology, neurology, ophthalmology, and respiratory. He also talks about the trend of title deflation and how candidates should focus on the responsibilities and long-term opportunities rather than just the title. Kristiaan provides insights into compensation trends, including base salaries, bonuses, and long-term incentives. He also addresses the topic of work onsite vs. remote and how companies are expecting employees to be onsite two to three times a week. Finally, he shares advice on charting your path and being willing to do what others won&#39;t to achieve your goals. <h2>Chapters</h2>00:00 - Introduction to the Biopharmaceutical Job Market02:05 - State of the Job Market and Layoffs in the Biopharmaceutical Industry03:31 - The Impact of the Great Resignation on the Pharmaceutical Industry06:07 - The Influence of Disease Areas on Hiring Trends08:30 - The Commercial Space in the Biopharmaceutical Industry12:55 - A Day in the Life of a Life Sciences Recruiter19:33 - Different Approaches and Business Models of Recruiters24:51 - How Candidates Should Approach Working with Recruiters27:49 - Building Long-Term Relationships with Recruiters32:00 - Success Stories of Candidates Who Overcame Challenges37:13 - The Impact of Technology on Job Applications43:48 - Hot Areas in the Industry48:23 - Title Deflation57:26 - Compensation Trends01:02:33 - Work Onsite vs. Remote01:09:01 - Charting Your Path <h2>Resources</h2><ul><li><a href="https://www.linkedin.com/in/kristiaan-rawlings-826772b5/" rel="nofollow">Kristiaan Rawlings LinkedIn</a></li><li><a href="https://www.epmscientific.com/" rel="nofollow">EPM Scientific</a></li><li><a href="https://www.biospace.com/article/biospace-layoff-tracker-2023-athenex-shutters-facility-cuts-staff/" rel="nofollow">Biopharma Layoff Tracker 2023</a></li><li><a href="https://www.biospace.com/article/what-to-expect-in-your-pharma-job-search/" rel="nofollow">BioSpace: How to Prepare for Your Biopharma Job Search</a></li></ul>

This episode discusses the biopharmaceutical job market and the impact of the COVID-19 pandemic. It explores the state of the job market, including layoffs and hiring trends in the industry. The conversation also delves into the role of recruiters in the life sciences industry and provides insights into their day-to-day activities.

Additionally, it offers advice for candidates on how to approach working with recruiters and highlights the importance of building long-term relationships. The episode concludes with a discussion on the impact of technology on job applications. In this conversation, Kristiaan discusses the current hot areas in the industry, including GLP-1s, dermatology, neurology, ophthalmology, and respiratory. He also talks about the trend of title deflation and how candidates should focus on the responsibilities and long-term opportunities rather than just the title. Kristiaan provides insights into compensation trends, including base salaries, bonuses, and long-term incentives.

He also addresses the topic of work onsite vs. remote and how companies are expecting employees to be onsite two to three times a week. Finally, he shares advice on charting your path and being willing to do what others won't to achieve your goals.


Chapters
00:00 - Introduction to the Biopharmaceutical Job Market
02:05 - State of the Job Market and Layoffs in the Biopharmaceutical Industry
03:31 - The Impact of the Great Resignation on the Pharmaceutical Industry
06:07 - The Influence of Disease Areas on Hiring Trends
08:30 - The Commercial Space in the Biopharmaceutical Industry
12:55 - A Day in the Life of a Life Sciences Recruiter
19:33 - Different Approaches and Business Models of Recruiters
24:51 - How Candidates Should Approach Working with Recruiters
27:49 - Building Long-Term Relationships with Recruiters
32:00 - Success Stories of Candidates Who Overcame Challenges
37:13 - The Impact of Technology on Job Applications
43:48 - Hot Areas in the Industry
48:23 - Title Deflation
57:26 - Compensation Trends
01:02:33 - Work Onsite vs. Remote
01:09:01 - Charting Your Path

Beyond the Job Title: Mastering the Pharma Job Market with Kristiaan Rawlings

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2024/1/25/15/b697f786-3bc3-4da8-8baa-0f20ccc2acf2_bioethics_-_caplan_-_final.mp3

Dr. Arthur Caplan, a distinguished bioethicist, discusses various topics related to bioethics. He highlights the importance of bioethics in areas such as organ transplantation, genetic testing, artificial intelligence, and personalized medicine.Dr. Caplan emphasizes the need for informed consent in research ethics and the importance of providing research participants with the results of studies. He also addresses the ethical considerations in organ transplantation, including the allocation of scarce resources and the role of living donors. Additionally, he discusses the ethical implications of expensive treatments and the allocation of limited resources in healthcare. The conversation explores the disparity in healthcare attention given to rare diseases compared to chronic conditions. It highlights the need for organized advocacy and lobbying for conditions that lack representation.The discussion also delves into the balance between investing in genetic therapies for rare diseases and preventive measures for chronic conditions. The ethical considerations of gene editing using CRISPR technology are examined, including the need for monitoring and surveillance of adverse effects. The potential for societal inequalities in access to gene editing is discussed, raising concerns about eugenics and the widening gap between those who can afford the technology and those who cannot.<h2>Chapters</h2>00:00 Introduction to Dr. Arthur Caplan01:35 The Importance of Bioethics in Various Areas09:25 Informed Consent in Research Ethics17:29 Balancing Scientific Progress and Ethical Considerations in Human Subject Research33:41 Ethical Considerations in Organ Transplantation47:22 Healthcare Resource Utilization and Pricing48:25 Disparity in Healthcare Attention51:18 Balancing Rare Diseases and Chronic Conditions53:36 Genetics vs. Environmental Intervention58:26 CRISPR and Bioethical Concerns01:05:13 Societal Inequalities in Access to Gene Editing01:06:03 Inspiration from Ben Franklin<h2>Resources</h2><ul><li><a href="https://med.nyu.edu/faculty/arthur-l-caplan" rel="nofollow">Dr. Arthur Caplan</a></li><li><a href="https://www.seattletimes.com/opinion/succumbing-to-ai-with-a-whimper-not-a-bang/" rel="nofollow">Succumbing to AI with a whimper, not a bang</a></li><li><a href="https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/research/working-group-compassionate-use-preapproval-access" rel="nofollow">Working Group on Compassionate Use and Preapproval Access (CUPA)</a></li><li><a href="http://vaccineworkinggroupethics.org/" rel="nofollow">Vaccine Working Group on Ethics and Policy</a></li><li><a href="https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/research/working-group-pediatric-gene-therapy-medical-ethics" rel="nofollow">Working Group on Pediatric Gene Therapy &amp; Medical Ethics</a></li><li><a href="https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/research/transplant-ethics-policy" rel="nofollow">Transplant Ethics and Policy </a></li><li><a href="https://www.opb.org/article/2024/01/22/if-you-donate-dna-what-should-scientists-give-in-return-a-pathbreaking-new-model/" rel="nofollow">If you donate DNA, what should scientists give in return? A ‘pathbreaking’ new model</a></li><li><a href="https://www.frontiersin.org/articles/10.3389/frtra.2023.1297957/full" rel="nofollow">Treating the dead; how far ought medicine go to obtain transplantable organs?</a></li><li><a href="https://pubmed.ncbi.nlm.nih.gov/38010648/" rel="nofollow">Consideration and Disclosure of Group Risks in Genomics and Other Data-Centric Research: Does the Common Rule Need Revision?</a></li><li><a href="https://pubmed.ncbi.nlm.nih.gov/38071588/" rel="nofollow">Research involving the recently deceased: ethics questions that must be answered</a></li><li><a href="https://pubmed.ncbi.nlm.nih.gov/37963043/#:~:text=As%20the%20pandemic%20made%20all,findings%20by%20concerted%20public%20engagement." rel="nofollow">Regaining Trust in Public Health and Biomedical Science following Covid: The Role of Scientists</a></li><li><a href="https://www.science.org/doi/10.1126/science.adh2746" rel="nofollow">Protect newborn screening programs</a></li><li><a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/hast.1501" rel="nofollow">Why the Gene Was (Mis)Placed at the Center of American Health Policy</a></li></ul>

Dr. Arthur Caplan, a distinguished bioethicist, discusses various topics related to bioethics. He highlights the importance of bioethics in areas such as organ transplantation, genetic testing, artificial intelligence, and personalized medicine.

Dr. Caplan emphasizes the need for informed consent in research ethics and the importance of providing research participants with the results of studies. He also addresses the ethical considerations in organ transplantation, including the allocation of scarce resources and the role of living donors. Additionally, he discusses the ethical implications of expensive treatments and the allocation of limited resources in healthcare. The conversation explores the disparity in healthcare attention given to rare diseases compared to chronic conditions. It highlights the need for organized advocacy and lobbying for conditions that lack representation.

The discussion also delves into the balance between investing in genetic therapies for rare diseases and preventive measures for chronic conditions. The ethical considerations of gene editing using CRISPR technology are examined, including the need for monitoring and surveillance of adverse effects. The potential for societal inequalities in access to gene editing is discussed, raising concerns about eugenics and the widening gap between those who can afford the technology and those who cannot.



Chapters
00:00 Introduction to Dr. Arthur Caplan

01:35 The Importance of Bioethics in Various Areas

09:25 Informed Consent in Research Ethics

17:29 Balancing Scientific Progress and Ethical Considerations in Human Subject Research

33:41 Ethical Considerations in Organ Transplantation

47:22 Healthcare Resource Utilization and Pricing

48:25 Disparity in Healthcare Attention

51:18 Balancing Rare Diseases and Chronic Conditions

53:36 Genetics vs. Environmental Intervention

58:26 CRISPR and Bioethical Concerns

01:05:13 Societal Inequalities in Access to Gene Editing

01:06:03 Inspiration from Ben Franklin

Navigating the Ethical Maze: Dr. Arthur Caplan on Bioethics in Modern Medicine

https://s3.us-east-2.amazonaws.com/pod-public-media-files/2023/12/9/20/6211d560-1791-41e7-8bf9-3dcee0e39bda_rp000_v2.mp3

Coming January 2024! RealPharma Podcast is your gateway to the world of biopharmaceuticals and healthcare. Your hosts are two industry veterans who engage in in-depth conversations with pharma pathfinders/leaders who are shaping the future of medicine. Hear the stories behind the news that challenge traditional viewpoints and offer fresh perspectives that will make you rethink what you know about the healthcare industry.

Trailer

For biopharma pros seeking insightful discussions and a deeper understanding of the pharma world, join Dr. Na-Ri Oh and Ian Wendt as they talk with industry leaders and luminaries to delve into biotechnology, pharmaceuticals, and healthcare.

RealPharma podcast aims to challenge your viewpoints, deepen your understanding of the pharma world beyond the headlines, and explore emerging trends in medical innovation.